Laminar, Inc.

Laminar, Inc. is a medical device company dedicated to developing solutions for eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Their core technology features a rotational motion device designed to address the LAA, which can be a source of blood clots and increase stroke risk in AFib patients. Laminar's approach aims to reduce the incidence of stroke by effectively targeting this risk factor. In November 2023, Laminar was acquired by Johnson & Johnson MedTech and now operates as part of Biosense Webster, Inc. This integration allows Laminar to utilize Biosense Webster’s global resources and expertise to enhance its reach among interventional cardiologists and electrophysiologists. The company has received FDA approval to begin a pivotal U.S. clinical study in 2024, highlighting its commitment to advancing treatment options for AFib patients. Laminar's primary customers are cardiac specialists focused on managing stroke risk in this patient population.

• Employees 21